"Chinese Journal of Hepatology" published an important article on liver cancer screening and monitoring Genetron Health HCCscreen was recognized by experts

Beijing, October 28, 2021/PRNewswire/ - On October 28, the Chinese Journal of Hepatology authoritatively released the contents of "Screening and Surveillance for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus", covering 12 provinces in China In the municipality directly under the central government, 29 tertiary hospitals, including domestic academicians in the field of liver disease and 34 authoritative experts in the field of liver disease, refer to relevant domestic and foreign guidelines, and combine current research progress and clinical practice experience to discuss and reach consensus, aiming to standardize development The screening and monitoring of hepatocellular carcinoma in patients with chronic hepatitis B virus infection can provide a reference to improve the prevention and control effect of hepatocellular carcinoma in China and the prognosis of patients
.

Picture: "Chinese Journal of Hepatology" authoritatively publishes the contents of "Screening and Surveillance of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection"

The article proposes that “the new biomarkers based on liquid biopsy have shown good application potential in the preliminary research of HCC diagnosis”; it further shows that “the application of the M2P-HCC model for HCC screening and monitoring will be possible to provide more AFP has higher sensitivity and specificity"
.

The M2P-HCC model is a liver cancer early screening model originally developed by Genetron Health (Nasdaq: GTH), a leading global cancer precision medicine company.

"Screening and Surveillance of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection" will provide clinical reference

Hepatocellular carcinoma is a common malignant tumor in China, and the burden of disease is very heavy
.

In 2020, there will be more than 900,000 new cases of primary liver cancer worldwide, ranking sixth in malignant tumors, and nearly half of them are in China[1]

Screening and monitoring are effective measures to improve the early diagnosis and treatment and survival rate of patients with hepatocellular carcinoma
.

Despite the continuous advancement of diagnosis and treatment technology in recent years, the 5-year survival rate of hepatocellular carcinoma patients is not ideal.

Chronic hepatitis B virus infection is the main cause of hepatocellular carcinoma in China, and up to 86% of patients with hepatocellular carcinoma are related to chronic hepatitis B virus infection [2]
.

The positive rate of serum HBsAg in the general population in China is 5% to 6%, and it is estimated that there are 70 million cases of chronic hepatitis B virus infection [3]

This time, the China Hepatitis Prevention Foundation project expert group organized multiple rounds of expert discussions and reached consensus, and finally formed the "Chronic Hepatitis B Virus Infected Patients Hepatocellular Carcinoma Screening and Surveillance", which will standardize the development of chronic hepatitis B virus infections Provide reference for screening and monitoring of hepatocellular carcinoma
.

HCCscreen™ innovative products based on the M2P-HCC model will likely provide higher sensitivity and specificity than AFP

In March 2021, Genetron Health released the latest data from a prospective large-scale cohort HIT study for early screening of liver cancer
.

After completing the follow-up of 1615 hepatitis B surface antigen-positive patients, the data showed that the HCCscreen™ based on the original M2P-HCC model of Genetron Health achieved 88% sensitivity and 93% specificity, which is significantly better than ultrasound combined with A fetus Protein (AFP) detection has a sensitivity of 71% and a specificity of 95%

In this regard, the "Screening and Monitoring of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infected Persons" highly recognized, and pointed out the future application scenarios and fields.
A prospective screening cohort study (HCCscreen™ Investigational Study, HIT study, ChiCTR1800020233), which aims to explore whether the M2P-HCC model can be used for early warning, screening and monitoring of HCC through the application of HCCscreen™ to screen HBsAg-positive adult HCC.
The M2P-HCC model for HCC screening and monitoring will likely provide higher sensitivity and specificity than AFP
.

"

Picture: Starlight Project Kick-off Meeting

Academic guidance "Starlight" project promotes three-level prevention

The occurrence and development of liver cancer has gone through a long process.
Scientifically identifying high-risk populations, formulating graded testing plans, paying attention to and strengthening the three-level prevention system for liver disease, has become the top priority for improving the overall survival rate of liver cancer
.

On October 8, the launching meeting of "Hepatitis B Surface Antigen Positive Adult Liver Cancer Screening and Monitoring Management Training" ("Starlight" Project) initiated by the China Hepatitis Prevention Foundation and supported by Genetron Health was officially held
.

Professor Lin Bingliang, the Third Affiliated Hospital of Sun Yat-sen University, Director Li Zengde, China Hepatitis Prevention Foundation, Professor Peng Jie, Southern Hospital of Southern Medical University, Professor Zhang Yuexin, First Affiliated Hospital of Xinjiang Medical University, Professor Yi Jianhua, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Guangzhou Professor Tang Xiaoping of Medical University, Director Zeng Zhaochang, member of the Hainan Provincial Health Commission, Executive Vice Chairman Yang Xizhong of China Hepatitis Prevention and Treatment Foundation, Professor Lin Feng of Hainan Provincial People's Hospital, Professor Chong Yutian of the Third Affiliated Hospital of Sun Yat-sen University, Professor Yang Ruifu of the Academy of Military Medical Sciences, Dr.

In the future, the "Starlight" project will rely on the "Screening and Surveillance of Hepatocellular Carcinoma for Patients with Chronic Hepatitis B Virus Infection".
It plans to use one year to cover public hospitals in prefecture-level cities and above across the country and hold regional, city, and department training.
More than 100 meetings will be held for more than 3,000 professional doctors and medical staff to cultivate the early detection and early diagnosis capabilities of chronic hepatitis B virus-related liver cancer, improve the concept of early screening, so that patients can detect liver cancer at an early stage, and improve the construction of an efficient The third-level liver disease prevention and diagnosis and treatment network has benefited more liver disease patients and high-risk groups
.

Genetron Health Co-founder and CEO Wang Sizhen said: "Since the first important paper published in the Proceedings of the National Academy of Sciences (PNAS) in 2019, Genetron Health has made significant progress in advancing the clinical application of HCCscreen™
.

I am glad that many authoritative and clinical experts in the industry have reached consensus on the application prospects of Genetron Health's early screening innovative technology and prospective research results

references:

[1] GLOBOCAN 2020 [Z].

[2] Wang MJ, Wang YT, Feng XS, et al.
Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center[J].
Int J Infect Dis, 2017, 65: 15-21.
DOI: 10.
1016/j.
ijid.
2017.
09.
003.

[3] Liu J, Liang WN, Jing WZ, et al.
Countdown to 2030: eliminating hepatitis B disease, China[J].
Bull World Health Organ, 2019, 97(3): 230-238.
DOI: 10.
2471/BLT .
18.
219469.

Source: Genetron Health